T cells expressing the CD19/CD22 CAR eradicated xenografts from ALL cell lines and patient-derived xenografts (PDX), including a PDX generated from a patient who relapsed with CD19- disease following CD19-directed CAR therapy. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.